Massachusetts Financial Services Co. MA Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Massachusetts Financial Services Co. MA cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 83.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,240 shares of the biopharmaceutical company’s stock after selling 575,988 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Alnylam Pharmaceuticals were worth $21,484,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after acquiring an additional 30,608 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after purchasing an additional 364,021 shares during the last quarter. Northern Trust Corp grew its position in Alnylam Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 797,700 shares of the biopharmaceutical company’s stock worth $141,273,000 after purchasing an additional 25,230 shares during the period. Ameriprise Financial Inc. raised its stake in Alnylam Pharmaceuticals by 12.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 706,200 shares of the biopharmaceutical company’s stock valued at $125,066,000 after buying an additional 80,862 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.9% during the 3rd quarter. American Century Companies Inc. now owns 442,743 shares of the biopharmaceutical company’s stock valued at $78,410,000 after buying an additional 3,872 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $149.40 on Friday. The company has a 50 day moving average price of $149.25 and a 200-day moving average price of $164.59. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $218.88. The firm has a market cap of $18.90 billion, a price-to-earnings ratio of -55.75 and a beta of 0.41.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same period in the previous year, the firm posted ($1.40) EPS. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 2nd. Citigroup dropped their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a report on Friday, February 16th. HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Chardan Capital restated a “buy” rating and issued a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $216.19.

Check Out Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.